Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

(2021) Justin F Gainor et al.   LANCET ONCOLOGY

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

(2021) Vivek Subbiah et al.   Lancet Diabetes & Endocrinology

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues

(2020) Massimo Santoro et al.   Genes

Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: Case series and literature review

(2020) Farhan Khalid et al.   Hematology/ Oncology and Stem Cell Therapy

Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.

(2019) Matthew H. Taylor et al.   JOURNAL OF CLINICAL ONCOLOGY

The global prevalence of latent tuberculosis: a systematic review and meta-analysis

(2019) Adam Cohen et al.   EUROPEAN RESPIRATORY JOURNAL

Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations

(2019) Amalia Anastasopoulou et al.   Journal for ImmunoTherapy of Cancer

Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib

(2019) Elena Maria Elli et al.   Frontiers in Oncology

Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention

(2018) Jean-Frédéric Colombel   INFLAMMATORY BOWEL DISEASES

Prevalence and risk factors of latent tuberculosis among Korean healthcare workers using whole-blood interferon-γ release assay

(2018) Jeong Hwa Yeon et al.   Scientific Reports

The emerging safety profile of JAK inhibitors in rheumatic disease

(2017) Kevin L. Winthrop   Nature Reviews Rheumatology

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy

(2017) Kevin L. Winthrop et al.   Arthritis & Rheumatology

RECIST 1.1—Update and clarification: From the RECIST committee

(2016) Lawrence H. Schwartz et al.   EUROPEAN JOURNAL OF CANCER

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

(2015) K L Winthrop et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550)

(2012) Mamoudou Maiga et al.   JOURNAL OF INFECTIOUS DISEASES

Solid-organ malignancy as a risk factor for tuberculosis

(2008) Hye-Ryoun KIM et al.   RESPIROLOGY